Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center by Smith, Kristen W. et al.
 
Urinary Paraben Concentrations and Ovarian Aging among
Women from a Fertility Center
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Smith, Kristen W., Irene Souter, Irene Dimitriadis, Shelley
Ehrlich, Paige L. Williams, Antonia M. Calafat, and Russ Hauser.
2013. “Urinary Paraben Concentrations and Ovarian Aging
among Women from a Fertility Center.” Environmental Health
Perspectives 121 (11-12): 1299-1305. doi:10.1289/ehp.1205350.
http://dx.doi.org/10.1289/ehp.1205350.
Published Version doi:10.1289/ehp.1205350
Accessed February 19, 2015 2:56:03 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879222
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAEnvironmental Health Perspectives  •  volume 121 | number 11-12 | November-December 2013  1299
Research
All EHP content is accessible to individuals with disabilities. A fully accessible (Section 508–compliant) 
HTML version of this article is available at http://dx.doi.org/10.1289/ehp.1205350. 
Urinary Paraben Concentrations and Ovarian Aging among Women 
from a Fertility Center
Kristen W. Smith,1 Irene Souter,2 Irene Dimitriadis,1,2 Shelley Ehrlich,1 Paige L. Williams,3 Antonia M. Calafat,4 and 
Russ Hauser1,2
1Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA; 2Department of Obstetrics and 
Gynecology, Division of Reproductive Endocrinology and Infertility, Harvard Medical School/Massachusetts General Hospital Fertility 
Center, Boston, Massachusetts, USA; 3Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; 
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Background: Parabens are preservatives commonly used in personal care products, pharma  ceuticals, 
and foods. There is documented widespread human exposure to parabens, and some experi  mental 
data suggest that they act as estrogenic endocrine disruptors. As far as we are aware, no epidemiologic 
studies have assessed female reproductive health effects in relation to paraben exposure.
oBjective: We examined the association of urinary paraben concentrations with markers of ovarian 
reserve in a prospective cohort study of women seeking fertility treatment at Massachusetts General 
Hospital, Boston, Massachusetts.
Methods: Measures of ovarian reserve were day-3 follicle-stimulating hormone (FSH), antral follicle 
count (AFC), and ovarian volume. Paraben concentrations [methyl  paraben (MP), propylparaben 
(PP), and butyl  paraben (BP)] were measured in spot urine samples collected prior to the assessment 
of outcome measures. We used linear and Poisson regression models to estimate associations of 
urinary paraben concentrations (in tertiles) with ovarian reserve measures.
results: Of the women enrolled in 2004–2010, 192 had at least one ovarian reserve outcome 
measured (mean age ± SD, 36.1 ± 4.5 years; range, 21.0–46.7 years). MP and PP were detected in 
> 99% of urine samples and BP in > 75%. We found a suggestive trend of lower AFC with increas-
ing urinary PP tertiles [mean percent change (95% CI) for tertiles 2 and 3 compared with tertile 1, 
respectively, were –5.0% (–23.7, 18.4) and –16.3% (–30.8, 1.3); trend p-value (ptrend) = 0.07] 
as well as higher day-3 FSH with higher urinary PP tertiles [mean change (95% CI) for ter-
tiles 2 and 3 compared with tertile 1 were 1.16 IU/L (–0.26, 2.57) and 1.02 IU/L (–0.40, 2.43); 
ptrend = 0.16]. We found no consistent evidence of associations between urinary MP or BP and 
day-3 FSH or AFC, or between urinary MP, PP, or BP and ovarian volume.
conclusions: PP may be associated with diminished ovarian reserve. However, our results require 
confirmation in further studies.
citation: Smith KW, Souter I, Dimitriadis I, Ehrlich S, Williams PL, Calafat AM, Hauser R. 
2013. Urinary paraben concentrations and ovarian aging among women from a fertility center. 
Environ Health Perspect 121:1299–1305;  http://dx.doi.org/10.1289/ehp.1205350
Introduction
Parabens are a family of chemicals commonly 
used as antimicrobial preservatives in per-
sonal care products, pharmaceuticals, and 
foods (Andersen 2008; National Toxicology 
Program 2005; Orth 1980). Exposure to 
parabens can occur through ingestion, inhala-
tion, or dermal absorption. Following excre-
tion, the parent compounds can be measured 
in urine and have been shown to be valid 
biomarkers of exposure (Ye et al. 2006a).
Although parabens are quickly eliminated 
from the body (Janjua et al. 2008), they have 
been detected in the general U.S. popula-
tion (Calafat et al. 2010; Ye et al. 2006a). 
Methylparaben (MP) and propyl  paraben 
(PP), the two most commonly used parabens 
(Soni et al. 2005), were detected in > 92% of 
a representative sample of the U.S. popula-
tion in the National Health and Nutrition 
Examination Survey (NHANES), whereas 
butyl  paraben (BP) was detected in 47% of 
participants (Calafat et al. 2010). Parabens 
have been detected in urine samples collected 
from infants (Calafat et al. 2009) and older 
children (Calafat et al. 2010; Casas et al. 
2011; Wolff et al. 2010), in adults of repro-
ductive age and older (Calafat et al. 2010; 
Meeker et al. 2011), and in pregnant women 
(Casas et al. 2011; Philippat et al. 2012; 
Smith et al. 2012), suggesting that exposure 
to parabens is ubiquitous and may begin in 
early life and extend throughout the lifespan.
Parabens are suspected endocrine disrup-
tors; they are estrogenic (Golden et al. 2005; 
Routledge et al. 1998; Soni et al. 2005), 
although they have a lower estrogen receptor 
binding affinity than does endogenous estro-
gen (Routledge et al. 1998; Vo et al. 2010). 
Parabens have been shown to bind to both 
estrogen receptor (ER)-α and ER-β (Gomez 
et al. 2005; Okubo et al. 2001). The estrogenic 
activity of parabens increases with increasing 
length and branching of the alkyl chain (e.g., 
BP > PP > MP) (Byford et al. 2002; Routledge 
et al. 1998; Vo et al. 2010).
On the basis of available toxicologic 
data, MP and PP were classified as generally 
regarded as safe (GRAS) in 1972 by the U.S. 
Food and Drug Administration (FDA 2013). 
In 2008, the Cosmetic Ingredient Review 
Panel concluded that parabens used in cos-
metics, including BP, do not pose a safety risk 
based on the available data (Andersen 2008). 
A few recent animal toxicity studies have 
reported adverse effects of some parabens on 
female reproductive and endocrine function 
(Kang et al. 2002; Taxvig et al. 2008; Vo 
et al. 2010). In one study evaluating pre-
pubertal female rats treated orally with para-
bens, effects included—but were not limited 
to—a decrease in ovarian weight and histo-
pathological changes in the ovaries, as well 
as altered estradiol and tetra  iodo  thyronine 
(T4), but not thyroid-stimulating hormone 
(TSH) levels (Vo et al. 2010). In that study, 
effects were seen with MP, BP, isopropyl-
paraben, and isobutyl  paraben, and the rela-
tionships varied by outcome, some of which 
were dose dependent. 
In a study evaluating pregnant rats exposed 
subcutaneously to parabens, together with 
their prenatally exposed fetuses, Taxvig et al. 
(2008) observed a decrease in ER-β expres-
sion in the ovaries of BP-exposed female 
fetuses. (ER-β gene expression was significantly 
decreased in animals exposed to either of the 
BP doses adminis  tered compared with the 
control, but it is unclear whether gene expres-
sion differed between the BP doses.) However, 
these researchers observed no change in ovar-
ian estradiol levels or ovarian histopathology. 
In addition, Taxvig et al. (2008) found no 
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association of maternal or fetal reproductive 
hormone levels with ethyl  paraben or BP expo-
sure. In another study of pregnant rats exposed 
subcutaneously to BP, Kang et al. (2002) 
found no evidence of effects on reproductive 
organ weights and no histopathological abnor-
malities in female offspring. 
Overall, these limited studies suggest that 
some parabens may exert adverse endocrine-
disrupting effects on female animals, but 
additional toxicologic data, including mecha-
nistic studies, are needed. Human data on the 
reproductive health effects of paraben expo-
sure are limited, and as far as we are aware, 
no studies have reported on the association of 
urinary paraben concentrations with female 
reproductive health outcomes.
Given the suspected endocrine-disrupting 
properties of parabens and the sensitivity of 
oogenesis to proper estrogen signaling, we were 
interested in evaluating the potential associa-
tion between urinary paraben concen  tra  tions 
and markers of ovarian reserve. Hormonal and 
ultra  sonographic markers of ovarian reserve 
are commonly used by repro  duc  tive endo-
crinology and infertility specialists to evaluate 
a woman’s response to ovarian stimu  la  tion, 
and include serum concen  tra  tion of follicle-
stimulating hormone (FSH) on day 3 of the 
menstrual cycle, antral follicle count (AFC), 
and ovarian volume (OV). Typically, as a 
woman’s age increases, her ovarian reserve 
diminishes (“ovarian aging”); this is associated 
with reduced fertility. Among women under-
going assisted reproduc  tive tech  nology (ART), 
ovarian aging is also associated with a decreased 
response to ovarian stimu  la  tion protocols 
and lower pregnancy success rates (Elter et al. 
2005; Levi et al. 2001). This diminished 
ovarian reserve is generally indicated by higher 
day-3 FSH levels and lower AFC and OV. 
However, there are factors other than age 
that could be associated with a diminished 
ovarian reserve, possibly including exposure to 
endocrine-disrupting chemi  cals. Therefore, the 
objective of this study was to evaluate whether 
exposure to parabens, assessed from urinary 
paraben concen  trations, is associated with 
diminished ovarian reserve among women 
under going  in vitro fertilization or intra  uterine 
insemination. 
Methods
Participants. Study participants were female 
patients from the Massachusetts General 
Hospital (MGH) Fertility Center who 
were under  going infertility evalua  tion and 
participating in our on  going prospective 
cohort study on environ  mental risk factors 
for reproductive health (Environment and 
Reproductive Health Study). The participants 
had at least one hormonal or ultra  sonographic 
marker of ovarian reserve measured (day-3 
FSH, AFC, or OV) and also contributed 
at least one urine sample for the measure-
ment of paraben concentrations prior to 
the measurement of the markers of ovarian 
reserve. All female patients > 18 years of age 
and < 46 years (at enrollment) seeking infer-
tility evaluation or treatment at the MGH 
Fertility Center were eligible to participate 
(close to 100% of patients were eligible) and 
approximately 60% consented. We excluded 
participants who previously had an oopho-
rectomy (n = 5). We recruited participants 
between December 2004 and October 2010 
and followed them from study entry until the 
discontinuation of fertility treatment, a live 
birth, or loss to follow-up. Two patients reen-
rolled in the study after the end of the initial 
follow-up period; only data from their first 
enrollment were included in this analysis. The 
study was approved by the Human Studies 
Institutional Review Boards of the MGH, 
Harvard School of Public Health (HSPH), 
and the Centers for Disease Control and 
Prevention (CDC). Participants signed an 
informed consent after the study procedures 
were explained by a research nurse and all 
questions were answered.
Clinical data. Clinical information 
was abstracted from the patient’s electronic 
medical record by a research nurse. An intra-
venous blood sample was drawn on the third 
day of the menstrual cycle, and the serum 
was analyzed for FSH with an automated 
electro chemiluminescence  immuno assay  at 
the MGH Core Laboratory, as previously 
described (Mok-Lin et al. 2010). AFC and 
OV were measured for both ovaries by a 
reproductive endocrinology and infertility 
specialist at the MGH Fertility Center using 
trans  vaginal ultra  sound. We calculated the 
OV using the following formula: [length 
(milli  meters) × width (milli  meters) × height 
(milli  meters)] × (π/6). We used the sum of 
antral follicles from the left and right ovaries 
(AFC) and the average volume of left and 
right ovaries (OV) in the analysis. Subsequent 
to an infertility evaluation, each patient was 
given an infertility diagnosis by a physician at 
the MGH Fertility Center according to the 
Society for Assisted Reproductive Technology 
(SART) definitions, as previously described 
(Mok-Lin et al. 2010). The participant’s date 
of birth and demographic charac  teristics were 
collected using a nurse-administered question-
naire at entry into the study, and weight and 
height were measured by the nurse. 
Urinary paraben measurements. We col-
lected a convenience spot urine sample from 
the women at the time of recruitment and 
at subsequent visits during infertility treat-
ment cycles. Although participants were 
recruited into this study beginning in 2004, 
the measure  ment of parabens in urine did not 
begin until August 2005, when these chemi-
cals were added to the study protocol. We 
collected samples between August 2005 and 
November 2010. Urine was collected in a 
sterile poly  propylene cup. After measuring 
specific gravity (SG) using a handheld refrac-
tometer (National Instrument Company, 
Inc., Baltimore, MD), the urine was divided 
into aliquots and frozen at –80°C. Samples 
were shipped on dry ice overnight to the 
CDC, where concentrations of total (free plus 
conjugated) MP, PP, and BP were measured 
using online solid-phase extraction–high 
performance liquid chromatography–isotope 
dilution tandem mass spectrometry, as previ-
ously reported (Ye et al. 2006b). Standard 
QA/QC procedures were followed (CDC 
2010b). The limits of detection (LODs) were 
1.0 μg/L for MP and 0.2 μg/L for PP and BP.
Statistical analysis. Demographic charac-
teristics of the study participants (mean and 
percentage) are reported separately for each 
outcome measure because the number of 
partici  pants varied by outcome. These charac-
teristics are also reported for partici  pants with 
any ovarian reserve outcome measured. The 
distribution of day-3 FSH, AFC, and OV 
are described using the mean ± SD, median 
and inter  quartile range (IQR), and range. We 
computed the within-person geometric mean 
(GM) of all urinary paraben concentrations 
(MP, PP, and BP) measured prior to outcomes 
as a summary exposure measure for each par-
ticipant. We summarized the distribution of 
exposures using the median, IQR, and range of 
urinary paraben concentrations. We assigned 
urinary concentrations below the LOD with a 
value equal to the LOD divided by the square 
root of two (Hornung and Reed 1990). We 
corrected urinary paraben concentrations 
for SG using a modification of a previously 
described formula (Duty et al. 2005): 
Pc = P[(1.016 – 1)/SG – 1], 
where Pc is the SG-corrected paraben concen-
tration (micrograms per liter), P is the mea-
sured paraben concentration (micrograms per 
liter), and 1.016 is the mean (and median) 
SG level in the study population. We used 
SG-corrected paraben concentrations in all 
analyses. We calculated the Spearman correla-
tion (rS) between the within-person GMs of 
the different parabens. 
We calculated the rS between the markers 
of ovarian reserve (day-3 FSH, AFC, and 
OV), age, and body mass index (BMI; kilo-
grams per meter squared). Among women 
with outcome measures available for each pair 
of correlations, we calculated the correla  tion 
between FSH and AFC, FSH and OV, and 
AFC and OV. We calculated the correla  tion 
of age and BMI with each separate outcome 
measure using all available measurements. We 
were interested in evaluating the associa  tion 
between BMI and these measures of ovarian Parabens and ovarian aging
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reserve because a higher BMI has been shown 
to be associated with infertility (Pasquali et al. 
2003; Shah et al. 2011), although there is 
limited evidence in the litera  ture for an 
association between ovarian reserve measures 
and BMI (Su et al. 2008).
We used multivariable linear regression to 
estimate associations between within-person 
MP, PP, and BP GM concentrations (divided 
into tertiles) with day-3 FSH and OV. OV was 
natural log (ln)-transformed [ln(OV)] prior to 
all regression analyses to reduce skewness. We 
used Poisson regression to estimate associa-
tions between within-person MP, PP, and BP 
GM concentrations (divided into tertiles) with 
AFC. Covariates considered for inclusion in 
the regression models included age in years at 
the time of the outcome measure and BMI at 
entry into the study (both modeled as continu-
ous measures); these were also included when 
related to the outcome measure in univariate 
regression models (p < 0.20). We considered 
age cate  gorized into < 37 years and ≥ 37 years 
for inclusion as a covariate in a sensitivity 
analysis because the ability to become preg-
nant declines around 37 years of age among 
women in the U.S. population under  going 
ART (CDC 2010a). To allow for easier inter-
pretation of the results, we exponentiated the 
parameter estimates for the linear regression 
model evaluating ln(OV) and for the Poisson 
regression model evaluating ln(AFC). The 
mean percent change in the outcome from the 
lowest tertile of paraben concentrations is pre-
sented for these two outcomes (OV and AFC). 
We conducted all tests for trend by assigning 
each urinary paraben concentration tertile an 
ordinal integer value of 0 (lowest tertile) to 2 
(highest tertile).
As a sensitivity analysis, we reran the 
regression models for AFC and OV excluding 
patients diagnosed with poly  cystic ovarian 
syndrome (PCOS) because these women 
tend to have a higher AFC and larger OV 
than women without this disease. PCOS was 
defined using a SART diagnosis (primary, 
secondary, or tertiary) of ovulatory disorder.
In a secondary analysis, we combined the 
parabens using two methods. We first used an 
estrogen equivalency (EEQ) factor approach 
(Safe 1998; Shirai et al. 2012) using the 
following formula: 
EEQ(parabens) = (MPm × 1) + (PPm × 83.3)   
  + (BPm × 250), 
where MPm, PPm, and BPm are the SG- 
adjusted within-person GM molar concen-
tra  tions, and the potency factors come 
from an in vitro yeast-based estrogen 
assay (BP, ~ 10,000 times less potent than 
17β-estradiol; PP, ~ 30,000 times less 
potent; and MP ~ 2,500,000 less potent) 
(Routledge et al. 1998). Second, we summed 
the urinary paraben concentra  tions using the 
following formula: 
Σ(parabens) = MPm + PPm + BPm. 
We used multi  variable linear regression to 
separately evaluate the association between 
EEQ(parabens) and Σ(parabens) (both 
divided into tertiles) with day-3 FSH and OV. 
OV was ln-transformed prior to all regres-
sion analyses to reduce skewness. We used 
Poisson regression to analyze the association 
between EEQ(parabens) and Σ(parabens) 
(both divided into tertiles) with AFC. We 
conducted all statistical analy  ses using SAS, 
version 9.2 (SAS Institute Inc., Cary, NC) and 
considered two-sided significance levels < 0.05 
statistically significant.
This exploratory study provided 80% 
power to detect a difference of 2.11 IU/L 
in day-3 FSH or 0.38 mm3 in ln(OV), for 
comparing high or medium urinary paraben 
concentrations with low urinary paraben con-
centrations (0.67 SDs). Similarly, the study 
design provided 80% power for detecting a 
difference in AFC of 4.2, corresponding to a 
decrease of approximately 38% between high 
and low paraben urinary concentrations.
Results
A total of 193 women had at least one mea-
sure of ovarian reserve available and at least 
one urinary paraben concentration measure-
ment. We excluded one woman for which all 
urine samples had missing SG measurements, 
resulting in a final sample of 192 women. 
Because all outcome measures were not 
available for all participants, we evaluated 
each outcome separately using all available 
measure  ments: day-3 FSH was measured in 
110 women, AFC in 142 women, and OV 
in 109 women. There were 44 women with 
all three measures, 81 women with two 
measures, and 67 women with only one 
measure available. We collected 1–14 urine 
samples from each partici  pant (median in 
each data set, 1 sample/participant; range of 
means in all three data sets, 2.2–2.6 samples/
participant) that contributed to the GM sum-
mary exposure measure. The urine samples 
were collected between 0 (the same day) and 
1,145 days before the outcome measure for 
the AFC data set (mean ± SD, 142 ± 182 days; 
median, 94 days), and between 0 and 981 days 
before the FSH (mean ± SD, 157 ± 159 days; 
median, 108 days) and OV (mean ± SD, 
110 ± 128 days; median, 77 days) data sets. 
Women were primarily Caucasian, non-
smokers, and > 35 years of age, and had a 
mean BMI (± SD) of 25.4 ± 5.15 (Table 1). 
The SART diagnosis was most commonly 
female factor, followed by male factor and 
unexplained infertility (Table 1). There 
was no significant difference in age or the 
Table 1. Characteristics by ovarian reserve outcome of 192 women participants of a prospective fertility 
study at Massachusetts General Hospital enrolled between 2004 and 2010.
Characteristic
Day‑3 FSH 
(n = 110)
AFC  
(n= 142)
OV  
(n = 109)
Any ovarian reserve 
outcome measured 
(n = 192)
Age (years)
Mean ± SD 36.1 ± 4.67 36.3 ± 4.24 35.6 ± 4.64 36.1 ± 4.48a 
Range 22.0–45.3 21.0–44.8 21.7–46.7 21.0–46.7
BMI (kg⁄m2)b 
Mean ± SD 25.6 ± 5.54 25.3 ± 5.14 24.9 ± 4.70 25.4 ± 5.15
Range 17.3–42.4 17.5–40.5 17.5–40.5 17.3–42.4
Race [n (%)]
Caucasian 85 (77) 115 (81) 92 (84) 156 (81)
African American/black 8 (7) 6 (4) 5 (5) 10 (5)
Asian 5 (5) 9 (6) 7 (6) 10 (5)
Native American/Alaska Native 1 (1) 1 (1) 0 (0) 1 (1)
Other 11 (10) 11 (8) 5 (5) 15 (8)
Smoking history [n (%)]
Never 86 (78) 106 (75) 76 (70) 142 (74)
Former 20 (18) 29 (20) 27 (25) 42 (22)
Current 4 (4) 7 (5) 6 (5) 8 (4)
SART diagnosis [n (%)]c 
Female factor 48 (44) 60 (43) 40 (37) 81 (42)
Endometriosis 8 (7) 8 (6) 8 (7) 12 (6)
Tubal factor 8 (7) 10 (7) 5 (5) 13 (7)
Diminished ovarian reserve 14 (13) 18 (13) 9 (8) 23 (12)
Ovulation disorders 17 (16) 23 (16) 18 (17) 31 (16)
Uterine disorders 1 (1) 1 (1) 0 (0) 2 (1)
Male factor 31 (28) 32 (23) 30 (28) 49 (26)
Unexplained 23 (21) 40 (28) 31 (29) 50 (26)
Other 7 (6) 9 (6) 7 (6) 11 (6)
aFor women with more than one outcome measure, the woman’s age at each outcome measure was averaged, and 
this value was used to calculate the mean ± SD. bFSH data set, n = 109; OV data set, n = 108; among all women with any 
outcome measured, n = 191. cPrimary SART diagnosis; FSH data set, n = 109; AFC data set, n = 141; OV data set, n = 108; 
among all women with any outcome measured, n = 191. Smith et al.
1302  volume 121 | number 11-12 | November-December 2013  •  Environmental Health Perspectives
number of participants diagnosed with 
PCOS in each of the three outcome sub-
groups (data not shown). The mean day-3 
FSH was 7.39 ± 3.17 IU/L with a range of 
0.10–26.0 IU/L. The median (IQR) AFC 
sum (left and right ovaries) was 11 (7–15) 
with a range of 2–40. The median (IQR) OV 
was 4,928 mm3 (3,634–7,588) with a range 
of 1,359–27,834 mm3.
Urinary paraben concentrations were sim-
ilar to those in the general population; MP 
and PP were detected in > 99% of samples, 
and BP in > 75% (Table 2). In each of the 
three data sets, there was a strong correla-
tion between concentrations of MP and PP 
(rS range, 0.81–0.85) and a moderate cor-
relation for MP and BP (rS range, 0.40–0.47) 
and PP and BP (rS range, 0.43–0.46).
We assessed the correlation of day-3 FSH, 
AFC, and OV among women having out-
come measures for each pair of correlations. 
Among women with both FSH and AFC 
(n = 85), FSH was negatively correlated with 
AFC (r = –0.40, p = 0.002); among women 
with both FSH and OV (n = 49), FSH was 
negatively correlated with OV (r = –0.36, 
p = 0.01); and among women with both AFC 
and OV (n = 79), AFC was positively cor-
related with OV (r = 0.47, p < 0.0001). FSH 
was positively correlated with age (r = 0.29, 
p = 0.002) but not with BMI (r = –0.048, 
p = 0.62). AFC and OV were negatively cor-
related with age (r = –0.44, p < 0.001; and 
r = –0.21, p = 0.025, respectively) but not 
with BMI (r = 0.036, p = 0.67; and r = 0.040, 
p = 0.68, respectively).
PP concentration was positively related 
to day-3 FSH, with mean day-3 FSH higher 
in tertiles 2 and 3 than in tertile 1, although 
there was not a significantly increasing trend 
across tertiles: The mean level in tertile 3 
was similar to that in tertile 2 [trend p-value 
(ptrend) = 0.16]. For MP and BP, mean day-3 
FSH was also higher in tertiles 2 and 3 than 
in tertile 1, although the mean levels of both 
analytes were lower in tertile 3 compared with 
tertile 2 (ptrend of 0.64 and 0.60 for MP and 
BP, respectively) (Table 3). We observed a 
suggestive trend for lower AFC among 
women with higher PP concentrations, with 
the mean percent difference from tertile 1 in 
AFC decreasing across tertiles (ptrend = 0.07). 
For MP, the magnitude of the parameter 
estimates in tertiles 2 and 3 was similar to 
PP, although the trend was not significant 
(ptrend = 0.31). We observed no association 
between BP and AFC (Table 4). There was 
no evidence of an association between uri-
nary MP, PP, or BP concentration and OV 
(Table 5). Age was significantly negatively 
associated with AFC and OV and positively 
associated with FSH; thus, age was included 
as a covariate in all regression models as a 
continuous measure (age was not associated 
with the exposures), whereas BMI was not 
observed to be associated (p > 0.20) and was 
not included.
In a sensitivity analysis controlling for age 
categorized into < 37 years and ≥ 37 years, 
the association between day-3 FSH and PP 
became stronger: The mean difference in day-3 
FSH was 1.24 IU/L [95% confidence interval 
(CI): –0.18, 2.67] in tertile 3 [using age as a 
continuous covariate, the mean difference was 
1.02 (95% CI: –0.40, 2.43)], and 1.19 IU/L 
(95% CI: –0.22, 2.60) in tertile 2 [using age 
as a continuous covariate, the mean difference 
was 1.16 (95% CI: –0.26, 2.57)], both com-
pared with tertile 1 (with the ptrend of 0.08 
becoming borderline significant). Including 
the cate  gorized age variable, the association 
between day-3 FSH and MP became stronger, 
with a mean difference in day-3 FSH of 0.57 
IU/L (95% CI: –0.85, 1.99) in tertile 3, and 
of 1.21 IU/L (95% CI: –0.21, 2.63) in ter-
tile 2, both compared with the lowest tertile. 
Including the categorized age variable, the asso-
ciation between day-3 FSH and BP became 
stronger with a mean difference in day-3 FSH 
of 0.53 IU/L (95% CI: –0.89, 1.95) in ter-
tile 3, and of 1.10 IU/L (95% CI: –0.32, 2.52) 
in tertile 2, both compared with tertile 1. The 
ptrend values for MP and BP remained non-
significant when the categorized age variable 
was included. The relationship of MP, PP, 
and BP with AFC and OV was similar when 
including the categorized age variable com-
pared with the continuous age variable (data 
not shown).
Among patients with an available SART 
diagnosis (n = 1 missing from each data set), 
excluding PCOS patients (n = 25 in the AFC 
data set; n = 20 in the OV data set) and con-
trolling for age (continuous), the relationship 
of PP with AFC was attenuated (data not 
shown). Excluding PCOS patients altered 
Table 2. Distribution of urinary paraben concentrations (μg/L) measured among participants of a pro-
spective fertility study at Massachusetts General Hospital enrolled between 2004 and 2010, by ovarian 
reserve outcome.
Paraben n
Percent 
detecteda
Uncorrected concentration SG‑corrected concentration
Minimum Median (IQR) Maximum Minimum Median (IQR) Maximum
Day 3 FSH
MP 110 100.0 6.70 210 (75.2, 520) 4,400 10.8 249 (89.0, 549) 2,428
PP 110 99.7 0.20 49.6 (13.0, 89.3) 1,000 0.46 55.1 (22.5, 124) 727
BP 110 80.0 < LOD 2.08 (0.40, 6.58) 142 < LOD 2.83 (0.40, 9.60) 177
AFC
MP 142 100 3.00 180 (74.7, 400) 4,400 5.13 227 (84.4, 492) 2,428
PP 142 99.4 < LOD 37.1 (17.4, 83.4) 1,430 < LOD 52.1 (21.5, 110) 727
BP 142 78.4 < LOD 1.42 (0.30, 6.07) 142 < LOD 1.60 (0.33, 9.49) 177
OV
MP 109 100.0 3.00 158 (57.7, 343) 4,400 7.77 219 (72.2, 429) 2,428
PP 109 99.2 < LOD 35.5 (11.6, 88.7) 1,430 < LOD 61.0 (14.6, 110) 654
BP 109 75.8 < LOD 1.53 (0.30, 6.13) 142 < LOD 2.18 (0.45, 8.50) 102
LODs were 1.0 μg/L for MP and 0.2 μg/L for PP and BP. 
aPercentage of concentrations > LOD. Total samples with PP concentrations < LOD by data set: 1 of 290 (FSH), 2 of 310 
(AFC), 2 of 252 (OV); total samples with BP concentrations < LOD by data set: 58 of 290 (FSH), 67 of 310 (AFC), 61 of 252 (OV). 
Table 3. Estimated mean change in day-3 FSH (IU/L) by urinary paraben concentration tertile from linear 
regression models.
Paraben concentration (μg/L) n
Estimated mean change 
in FSH (95% CI)a p‑Value
MP
Tertile 3 (432–2,428) 37 0.35 (–1.07, 1.77) 0.63
Tertile 2 (154–430) 37 1.04 (–0.39, 2.46) 0.15
Tertile 1 (10.8–144) 36 0 (Reference)
ptrend  0.64
PP
Tertile 3 (87.8–727) 37 1.02 (–0.40, 2.43) 0.16
Tertile 2 (32.0–80.9) 37 1.16 (–0.26, 2.57) 0.11
Tertile 1 (0.46–29.4) 36 0 (Reference)
ptrend  0.16
BP
Tertile 3 (6.00–177) 37 0.39 (–1.03, 1.82) 0.59
Tertile 2 (0.96–5.61) 37 0.95 (–0.48, 2.39) 0.19
Tertile 1 (< LOD–0.85) 36 0 (Reference)
ptrend  0.60
All model results were adjusted for age; paraben concentrations were SG-corrected. LODs were 1.0 μg/L for MP and 
0.2 μg/L for PP and BP. 
aParameter estimates can be interpreted as an IU/L change in day-3 FSH for each tertile of urinary paraben concen-
tration relative to tertile 1 (reference). For example, in tertile 3 of the PP urinary concentrations, there is a 1.02-IU/L 
increase, on average, in day-3 FSH compared with tertile 1. Parabens and ovarian aging
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parameter estimates for associations of MP and 
BP with AFC and associations of MP, PP, and 
BP with OV, but estimates were imprecise and 
remained non  significant (data not shown).
In a secondary exploratory analysis evaluat-
ing the association of combined concentra-
tions of parabens with the three ovarian reserve 
outcomes (controlling for age as a continu-
ous measure), we found that EEQ(parabens) 
was negatively related to AFC in tertile 3, 
with a mean difference of –6.4% (95% CI: 
–24.4, 15.8), and little evidence of an asso-
ciation in tertile 2, with a mean difference 
of 1.1% (95% CI: –17.3, 23.5), both com-
pared with tertile 1, although the trend was 
not statistically signifi  cant (ptrend = 0.54) (see 
Supplemental Material, Table S1). Similarly, 
we found that Σ(parabens) was negatively 
related to AFC, with a mean difference of 
–10.8% (95% CI: –28.2, 10.7) in tertile 3, 
and of –6.5% (95% CI: –23.4, 14.1) in ter-
tile 2, both compared with tertile 1, although 
the trend was not statistically signifi  cant 
(ptrend = 0.30). We found no significant 
relationships between EEQ(parabens) or 
Σ(parabens) with day-3 FSH or OV (see 
Supplemental Material, Tables S2 and S3, 
respectively).
Discussion
As far as we are aware, this is the first epide-
miologic study to assess female reproductive 
health outcomes in relation to biomarkers 
of paraben exposure. We found that nearly 
100% of the women included in this study 
had detectable urinary concentrations of MP 
and PP, and > 75% of women had detectable 
BP concentrations. Urinary paraben concen-
trations were similar to those reported for 
all females from NHANES in 2005–2006 
(Calafat et al. 2010). In that study, median 
(IQR) unadjusted urinary paraben concen-
trations for women were 137 μg/L (35.4–
356 μg/L), 29.1 μg/L (5.30–93.0 μg/L), and 
0.50 μg/L (< LOD–3.70 μg/L) for MP, PP, 
and BP, respectively (Calafat et al. 2010). 
We found suggestive evidence of a negative 
relationship between urinary PP and AFC, 
considered one of the best markers of ovarian 
reserve (Rosen et al. 2012). Higher urinary 
PP was associated with a higher day-3 FSH, 
which is consistent with PP’s negative asso-
ciation with AFC. The positive relationship of 
urinary PP with day-3 FSH approached sta-
tistical significance when controlling for age 
categorized into < 37 years and ≥ 37 years, 
although the magnitude of the association 
was similar as when controlling for age as 
a continuous measure. These findings sug-
gest that exposure to PP may adversely 
affect ovarian reserve, and thus contribute 
to ovarian aging, among women attend-
ing a fertility clinic. Although evidence of a 
negative relationship between MP and AFC 
was suggestive, there was no clear evidence 
of associations between urinary MP or BP 
concentrations with any of the markers of 
ovarian reserve. Similar to the relationship 
between urinary PP and AFC, in an explor-
atory analysis the three parabens combined 
were negatively related to AFC using both 
EEQ(parabens) and Σ(parabens), although 
the relationship did not approach statistical 
significance. 
It has been established that parabens are 
estrogenic (Golden et al. 2005; Routledge 
et al. 1998; Soni et al. 2005) and that they 
bind to both ER-α and ER-β (Gomez et al. 
2005; Okubo et al. 2001). Although the 
estrogen receptor binding affinity of parabens 
is much lower than that of endogenous 
estrogen (Darbre and Harvey 2008), oogenesis 
is highly dependent on proper estrogen 
signaling (Hewitt et al. 2005); therefore, 
even slight changes in the ovarian hormonal 
environment (either in utero or later in life) 
could contribute to altered ovarian function. 
The relationship of PP with diminished 
ovarian reserve is consistent with animal data 
showing that the estro  genicity of parabens, 
and therefore the potential for reproductive 
toxicity, is greater in PP compared with MP 
(Byford et al. 2002; Routledge et al. 1998; Vo 
et al. 2010). Although the animal data also 
show that BP is more estrogenic than PP or 
MP, we detected BP less frequently; when it 
was detected, urinary concentrations of BP 
were much lower than those of either PP or 
MP, which may explain the lack of an associa-
tion of BP with markers of ovarian reserve. 
It is also possible that biological activity and 
mechanisms of action differ between the 
parabens. However, as far as we know, this has 
not been studied.
A few studies conducted in female rats 
and mice have suggested an association 
between paraben exposure and reproduc-
tive outcomes (Taxvig et al. 2008; Vo et al. 
2010). These outcomes include changes in 
ovarian weight and histo  pathology, as well 
Table 4. Estimated mean percent change in AFC by urinary paraben concentration tertile based on the 
Poisson regression model. 
Paraben concentration (μg/L) n
Estimated mean percent 
change in AFC (95% CI) p‑Value
MP
Tertile 3 (381–2,428) 47 –10.6 (–28.2, 11.2) 0.31
Tertile 2 (145–377) 48 –6.8 (–23.5, 13.7) 0.49
Tertile 1 (5.13–132) 47 0 (Reference)
ptrend  0.31
PP
Tertile 3 (87.8–727) 47 –16.3 (–30.8, 1.3) 0.07
Tertile 2 (26.3–81.8) 48 –5.0 (–23.7, 18.4) 0.65
Tertile 1 (< LOD–25.2) 47 0 (Reference)
ptrend  0.07
BP
Tertile 3 (5.44–177) 48 –2.0 (–21.0, 21.6) 0.86
Tertile 2 (0.75–5.12) 47 –4.8 (–22.5, 16.8) 0.63
Tertile 1 (< LOD–0.73) 47 0 (Reference)
ptrend  0.86
All model results were adjusted for age; paraben concentrations were SG-corrected. LODs were 1.0 μg/L for MP and 
0.2 μg/L for PP and BP. 
Table 5. Estimated mean percent change in OV by urinary paraben concentration tertile based on the 
linear regression model. 
Paraben concentration (μg/L) n
Estimated mean percent 
change in OV (95% CI) p‑Value
MP
Tertile 3 (332–2,428) 36 4.7 (–19.4, 35.9) 0.73
Tertile 2 (100–326) 37 15.0 (–11.2, 49.1) 0.29
Tertile 1 (7.77–95.7) 36 0 (Reference)
ptrend  0.73
PP
Tertile 3 (87.8–654) 36 –0.9 (–23.5, 28.3) 0.94
Tertile 2 (27.1–81.8) 37 19.2 (–8.0, 54.4) 0.18
Tertile 1 (< LOD–25.2) 36 0 (Reference)
ptrend  0.94
BP
Tertile 3 (6.02–102) 36 –4.2 (–26.1, 24.2) 0.74
Tertile 2 (0.82–5.43) 36 1.0 (–22.2, 31.2) 0.94
Tertile 1 (< LOD–0.80) 37 0 (Reference)
ptrend  0.74
All model results were adjusted for age; paraben concentrations were SG-corrected. LODs were 1.0 μg/L for MP and 
0.2 μg/L for PP and BP. Smith et al.
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as changes in ER-α and ER-β gene expres-
sion. In a study of pre  pubertal female mice 
treated orally with parabens, adverse effects 
included a decrease in ovarian weight (MP 
and isopropyl-paraben, but not PP or BP) 
and histo  pathological changes in the ovaries 
(MP, isopropyl-paraben, BP, and isobutyl-
paraben, but not PP) (Vo et al. 2010). These 
histopathological changes included a decrease 
in corpora lutea, an increase in the number 
of cystic follicles, and a thinning of follicular 
cells, which suggests that post  natal paraben 
exposure could adversely influence ovarian 
follicle development and thus potentially lead 
to diminished ovarian reserve. These changes 
could be a result of the estrogenic action of 
parabens. Similar effects have been observed 
in adult mice exposed to diethylstilbestrol 
(Hong et al. 2010).
In a study of pregnant rats treated subcu-
taneously with parabens, Taxvig et al. (2008) 
found a decrease in ER-β expression in the 
ovaries of female fetuses exposed to BP (MP 
and PP were not evaluated). In an in vitro 
study using MCF-7 human breast cancer 
cells, Okubo et al. (2001) found that ER-α 
expression decreased and progesterone recep-
tor (PR) expression increased after adminis-
tration of BP and isobutyl-paraben (MP and 
PP were not evaluated). It is possible that 
altered gene expression related to in utero 
paraben exposure could adversely affect the 
ovarian follicle pool. Proper estrogen signal-
ing is a key component in the development of 
the ovarian follicle pool in utero (Crain et al. 
2008), and disruption of this signaling could 
manifest as diminished ovarian reserve during 
a woman’s reproductive years. 
In a previous study including the same 
patients from the MGH Fertility Center, we 
found that one urine sample was reasonably 
representative of urinary paraben concentra-
tions over several months (intra  class correlation 
coefficients between 0.4 and 0.5 for MP, PP, 
and BP using non  pregnancy samples) (Smith 
et al. 2012). In the present study, because 
multiple samples were collected from some 
women, we used a summary exposure measure 
for each partici  pant by taking the geometric 
mean of all urine samples collected prior to the 
outcome measure. Although one urine sample 
may reasonably represent several months of 
exposure, one strength of our study is that the 
collection of multiple samples should reduce 
exposure misclassification during that time 
period. However, a limitation of this study is 
that the time period of collection of the urine 
samples was up to 3 years before the outcome 
measure. It is unknown whether the window 
of exposure that is most etiologically relevant 
to the outcomes assessed is the year prior to 
the outcome measure, for example, or any ear-
lier period in the life course (e.g., pubertal or 
even in utero exposure). If paraben exposure 
within several months prior to evaluation is 
the relevant window of exposure, the summary 
exposure measure used may reasonably repre-
sent the relevant exposure period. However, 
we believe that any exposure misclassification 
in this study is non  differential. In future stud-
ies with larger sample sizes, we recommend 
examination of the time window to determine 
whether samples collected closer in time (i.e., a 
3-month window) are more strongly associated 
with the outcome measures than are samples 
collected more remotely. 
Another limitation of the present study 
is the relatively small sample size, which may 
limit our ability to detect an association. In 
addition, not all women had all three of the 
outcome measures because they are all not 
always clinically performed. However, this 
study is the first of its kind, and we suggest 
further investigation using a larger sample size 
to detect potentially subtle changes in mark-
ers of ovarian reserve in response to suspected 
endocrine-disrupting chemicals. Inclusion in 
our study of the high proportion of Caucasians 
and older women, as well as the sole inclusion 
of women from a fertility clinic under  going 
in vitro fertilization or intra  uterine insemina-
tion, all with varied SART diagnoses, may also 
limit the generalizability of these findings to 
non-Caucasians, younger women, and women 
with no difficulties conceiving. Because of 
the numerous xeno  estrogens in personal care 
products, food, and medications (e.g. parabens, 
bisphenol A, benzo  phenone-3, triclosan), we 
suggest that future studies take into account 
the potential for the effect of estrogenic mix-
tures (e.g., assessing inter  actions between expo-
sure categories of the chemicals). Finally, there 
is also the possibility of bias from uncontrolled 
confounding, given that personal care product 
use may change with age.
Conclusion
The present study provides evidence suggest-
ing that exposure to PP may lead to dimin-
ished ovarian reserve and contribute to ovarian 
aging among women at an infertility clinic. 
It has been estimated that in 2002 there were 
> 7 million women with impaired fecundity 
in the United States, and > 5 million women 
were reported as seeking help to become preg-
nant (Chandra et al. 2005). This is a large sub-
population of women that may be especially 
sensitive to endocrine-disrupting chemicals. 
Finally, although the parabens evaluated for 
the present study are considered to be safe 
(have a GRAS designation) based on a 1972 
decision by the FDA (FDA 2013), given 
their widespread use and ubiquitous human 
exposure, further research using modern toxi-
cologic designs and end points may be war-
ranted. Our results suggest the need for future 
human studies to explore these associations in 
other populations with a larger sample size.
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